Asset Details
Do you wish to reserve the book?
Impulse control disorders in Parkinson’s disease: What’s new?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Impulse control disorders in Parkinson’s disease: What’s new?
Do you wish to request the book?
Impulse control disorders in Parkinson’s disease: What’s new?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Impulse control disorders in Parkinson’s disease: What’s new?
2025
Overview
Impulse Control Disorders (ICDs) are increasingly recognized as a significant non-motor complication in Parkinson’s disease (PD), impacting patients and their caregivers. ICDs in PD are primarily associated with dopaminergic treatments, particularly dopamine agonists, though not all patients develop these disorders, indicating a role for genetic and other clinical factors. Studies over the past few years suggest that the mesocorticolimbic reward system, a core neural substrate for impulsivity, is a key contributor to ICDs in PD. Recent advances in neuroimaging have begun to unravel the neurobiological diversity of ICD subtypes. Moreover, recent studies provide valuable insights into the clinical and biologic risk factors for ICDs that could be used as indicators for the development of future preventive strategies or targeted interventions. Indeed, current treatment strategies, which often involve reducing or discontinuing dopamine agonists, are limited in efficacy. Emerging therapies, including behavioral interventions and continuous drug delivery methods, show promise, though further research is needed. This paper provides an updated review of ICD prevalence, mechanisms, assessment, and novel management approaches.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
/ Disruptive, Impulse Control, and Conduct Disorders - diagnosis
/ Disruptive, Impulse Control, and Conduct Disorders - epidemiology
/ Disruptive, Impulse Control, and Conduct Disorders - etiology
/ Disruptive, Impulse Control, and Conduct Disorders - therapy
/ Dopamine
/ Humans
/ Medicine
/ Parkinson Disease - complications
/ Parkinson Disease - drug therapy
/ Parkinson Disease - epidemiology
/ Patients
